Sodium 2-hydroxy-5-((4-sulfonatophenyl)diazenyl)benzoate

Catalog No. :
ACNRCA054
CAS No. :
6054-99-5
Molecular Formula :
C13H8N2Na2O6S
Molecular Weight :
366.26

IUPAC Name:sodium (E)-2-hydroxy-5-((4-sulfonatophenyl)diazenyl)benzoate

Sodium 2-hydroxy-5-((4-sulfonatophenyl)diazenyl)benzoate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
500g95%$83.00Login to see priceIn stockInquiry
1000g95%$157.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameSodium 2-hydroxy-5-((4-sulfonatophenyl)diazenyl)benzoate
IUPAC Namesodium (E)-2-hydroxy-5-((4-sulfonatophenyl)diazenyl)benzoate
MDL No.MFCD00007504
Molecular FormulaC13H8N2Na2O6S
Molecular Weight366.26
SMILESOC1=CC=C(/N=N/C2=CC=C(S(=O)([O-])=O)C=C2)C=C1C([O-])=O.[Na+].[Na+]
InChI KeyYEVMULNVFDCUTD-NSKUCRDLSA-L
SynonymSCHEMBL428681 | Rolipram - CAS 61413-54-5 | Benzoic acid, 2-hydroxy-5-[(4-sulfophenyl)azo]-, disodium salt | MFCD00007504 | 2-hydroxy-5-((4-sulfophenyl)azo)benzoic acid | Acid Chrome Yellow | Chrome Yellow 2J | Eniacromo Yellow GR | Durochrome Yellow 2G |
CAS No.6054-99-5
PubChem CID135465067

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACNRCA054 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACNRCA054 route product structure diagram
    ACNRCA0546054-99-5 In Stock
Inquiry

2. ACNRCA054 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACKXBI037 route compound structure diagram
    ACKXBI03789-57-6 In Stock
  4. Then
  5. ACNRCA054 route product structure diagram
    ACNRCA0546054-99-5 In Stock
Inquiry

Comments (0)